TLDR:
- Wobble Genomics, a biotech spinout from the University of Edinburgh, raised £8.5m to commercialize its technology.
- The funding round was led by Mercia Ventures and BGF, with support from IQ Capital, EOS Advisors, and Old College Capital.
Biotech spinout, Wobble Genomics, has secured £8.5m in funding to advance its revolutionary RNA sequencing technology. Founded by Dr. Richard Kuo in 2021, the company specializes in long-read RNA sequencing and aims to double its team size in the next two years. The latest funding round, led by Mercia Ventures and BGF, brings the total raised amount to over £10.5m. Wobble’s technology allows for the detection of “full length” RNA, offering extensive applications in fields like drug development, agriculture, and ecology. By focusing on long-read sequencing, the company overcomes challenges associated with traditional short-read techniques, providing a deeper understanding of cellular behavior. With backing from leading life science investors, Wobble is poised to drive innovation in biotechnology.
Dr. Kuo, Wobble’s CEO, emphasized the potential of long-read RNA sequencing in revolutionizing biotechnology, expressing gratitude for the support from UK’s top life science investors. Meanwhile, investors like Lee Lindley of Mercia Ventures and Jo Smart of BGF highlighted the transformative impact of Wobble’s technology in precision medicine and early cancer detection. With a proven scientific foundation, Wobble is well-positioned to develop and commercialize its groundbreaking RNA sequencing technology, paving the way for exciting advancements in the biotech industry.
